JP2019504860A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504860A5 JP2019504860A5 JP2018542709A JP2018542709A JP2019504860A5 JP 2019504860 A5 JP2019504860 A5 JP 2019504860A5 JP 2018542709 A JP2018542709 A JP 2018542709A JP 2018542709 A JP2018542709 A JP 2018542709A JP 2019504860 A5 JP2019504860 A5 JP 2019504860A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cancer
- use according
- days
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 24
- 239000003814 drug Substances 0.000 claims 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 229940127089 cytotoxic agent Drugs 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 claims 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 3
- 230000033115 angiogenesis Effects 0.000 claims 3
- 229960002412 cediranib Drugs 0.000 claims 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 3
- 229910052697 platinum Inorganic materials 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 239000012661 PARP inhibitor Substances 0.000 claims 2
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims 2
- 229950009791 durvalumab Drugs 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- 206010073360 Appendix cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 208000021780 appendiceal neoplasm Diseases 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical group FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims 1
- 229960000572 olaparib Drugs 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000028617 response to DNA damage stimulus Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021064539A JP7271594B2 (ja) | 2016-02-15 | 2021-04-06 | セジラニブの一定間欠投与を含む方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662295421P | 2016-02-15 | 2016-02-15 | |
| US62/295,421 | 2016-02-15 | ||
| PCT/US2017/017804 WO2017142871A1 (en) | 2016-02-15 | 2017-02-14 | Methods comprising fixed intermittent dosing of cediranib |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021064539A Division JP7271594B2 (ja) | 2016-02-15 | 2021-04-06 | セジラニブの一定間欠投与を含む方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019504860A JP2019504860A (ja) | 2019-02-21 |
| JP2019504860A5 true JP2019504860A5 (enExample) | 2020-03-26 |
| JP6865762B2 JP6865762B2 (ja) | 2021-04-28 |
Family
ID=59625551
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018542709A Active JP6865762B2 (ja) | 2016-02-15 | 2017-02-14 | セジラニブの一定間欠投与を含む方法 |
| JP2021064539A Active JP7271594B2 (ja) | 2016-02-15 | 2021-04-06 | セジラニブの一定間欠投与を含む方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021064539A Active JP7271594B2 (ja) | 2016-02-15 | 2021-04-06 | セジラニブの一定間欠投与を含む方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210322415A1 (enExample) |
| EP (2) | EP4071174A1 (enExample) |
| JP (2) | JP6865762B2 (enExample) |
| KR (1) | KR102830910B1 (enExample) |
| CN (1) | CN109073650A (enExample) |
| AU (1) | AU2017221268B2 (enExample) |
| CA (1) | CA3014674C (enExample) |
| DK (1) | DK3417294T3 (enExample) |
| ES (1) | ES2906813T3 (enExample) |
| HU (1) | HUE058114T2 (enExample) |
| MA (1) | MA44251A (enExample) |
| MX (2) | MX2018009867A (enExample) |
| PL (1) | PL3417294T3 (enExample) |
| RU (1) | RU2740849C2 (enExample) |
| TW (1) | TWI827530B (enExample) |
| WO (1) | WO2017142871A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI879716B (zh) | 2017-05-09 | 2025-04-11 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| MA49144A (fr) | 2017-05-18 | 2020-03-25 | Tesaro Inc | Polythérapies pour le traitement du cancer |
| CA3076515A1 (en) | 2017-09-30 | 2019-04-04 | Tesaro, Inc. | Combination therapies for treating cancer |
| MA50618A (fr) * | 2017-10-06 | 2020-08-12 | Tesaro Inc | Polyrhérapies et leurs utilisations |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| BRPI0017548B8 (pt) | 1999-02-10 | 2023-05-02 | Astrazeneca Ab | Composto |
| AU2001258628A1 (en) | 2000-05-31 | 2001-12-11 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| BR0112225A (pt) | 2000-07-07 | 2003-05-06 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| MXPA04010199A (es) * | 2002-04-15 | 2005-07-05 | Sloan Kettering Inst Cancer | Terapia en combinacion para el tratamiento de cancer. |
| GB0330002D0 (en) | 2003-12-24 | 2004-01-28 | Astrazeneca Ab | Quinazoline derivatives |
| JP2008514576A (ja) * | 2004-09-27 | 2008-05-08 | アストラゼネカ アクチボラグ | Ａｚｄ２１７１およびイマチニブを含む癌組合せ療法 |
| US20090035317A1 (en) * | 2007-01-12 | 2009-02-05 | Daugherty Patrick S | Peptides binding to vascular endothelial growth factor |
| CA2715181A1 (en) * | 2008-02-21 | 2009-08-27 | Astrazeneca Ab | Combination therapy 238 |
| WO2010091140A1 (en) * | 2009-02-04 | 2010-08-12 | Bipar Sciences, Inc. | Treatment of lung cancer with a parp inhibitor in combination with a growth factor inhibitor |
| NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| HK1201828A1 (en) * | 2011-11-08 | 2015-09-11 | Intellikine, Llc | Treatment regimens using multiple pharmaceutical agents |
| JP6184423B2 (ja) * | 2012-05-18 | 2017-08-23 | 大日本住友製薬株式会社 | カルボン酸化合物 |
| WO2014066834A1 (en) * | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| EP3082853A2 (en) * | 2013-12-20 | 2016-10-26 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| NO2714752T3 (enExample) * | 2014-05-08 | 2018-04-21 | ||
| MX389663B (es) * | 2014-10-14 | 2025-03-20 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas. |
-
2017
- 2017-02-14 EP EP21211394.8A patent/EP4071174A1/en active Pending
- 2017-02-14 TW TW106104799A patent/TWI827530B/zh active
- 2017-02-14 WO PCT/US2017/017804 patent/WO2017142871A1/en not_active Ceased
- 2017-02-14 MA MA044251A patent/MA44251A/fr unknown
- 2017-02-14 CA CA3014674A patent/CA3014674C/en active Active
- 2017-02-14 AU AU2017221268A patent/AU2017221268B2/en active Active
- 2017-02-14 RU RU2018131377A patent/RU2740849C2/ru active
- 2017-02-14 MX MX2018009867A patent/MX2018009867A/es unknown
- 2017-02-14 JP JP2018542709A patent/JP6865762B2/ja active Active
- 2017-02-14 HU HUE17753704A patent/HUE058114T2/hu unknown
- 2017-02-14 US US16/077,720 patent/US20210322415A1/en not_active Abandoned
- 2017-02-14 DK DK17753704.0T patent/DK3417294T3/da active
- 2017-02-14 ES ES17753704T patent/ES2906813T3/es active Active
- 2017-02-14 CN CN201780011505.XA patent/CN109073650A/zh active Pending
- 2017-02-14 EP EP17753704.0A patent/EP3417294B8/en active Active
- 2017-02-14 KR KR1020187024215A patent/KR102830910B1/ko active Active
- 2017-02-14 PL PL17753704T patent/PL3417294T3/pl unknown
-
2018
- 2018-08-14 MX MX2023007826A patent/MX2023007826A/es unknown
-
2021
- 2021-04-06 JP JP2021064539A patent/JP7271594B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017530984A5 (enExample) | ||
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| JP2019504860A5 (enExample) | ||
| CY1121698T1 (el) | Υγρο σκευασμα για εισπνοη που περιεχει rpl554 | |
| JP2017226708A5 (enExample) | ||
| MX2015011896A (es) | Formulacion de liberacion sostenida de mosapride que proporciona efectos farmacologicos y clinicos con administracion una vez al dia. | |
| MX389346B (es) | Formulaciones de anticuerpos monoclonales de alta concentración. | |
| AR088458A1 (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y fingolimod | |
| JP2018505169A5 (enExample) | ||
| ME02946B (me) | Dimer buprenorfina i njegova upotreba u lecenju gastrointestinalnih poremecaja | |
| JP2015500225A5 (enExample) | ||
| ME02597B (me) | Inhibitori histonskih demetilaza | |
| JP2016530280A5 (enExample) | ||
| AU2016204185A1 (en) | Methods of administering beta7 integrin antagonists | |
| JP2019530706A5 (enExample) | ||
| JP2015522033A5 (enExample) | ||
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| JP2015514739A5 (enExample) | ||
| HRP20220317T1 (hr) | Otkrivanje i liječenje nedostatka hormona rasta | |
| JP2014523398A5 (enExample) | ||
| FI3383385T4 (fi) | Melflufeeniannoskuureja syöpään | |
| JP2017519006A5 (enExample) | ||
| JP2018522028A5 (enExample) | ||
| HRP20210010T1 (hr) | Injekcijske farmaceutske formulacije lefamulina | |
| JP2021505669A5 (enExample) |